Airway Therapeutics Welcomes Joe Todisco to Its Board of Directors

Airway Therapeutics, Inc. has taken an important step forward by announcing the appointment of Joe Todisco, a seasoned leader in the biopharmaceutical sector, to its board of directors. This move is expected to bolster the company's strategic direction as it continues to develop novel biologic therapies to address critical respiratory, inflammatory, and infectious diseases.

The board welcomed Todisco on April 13, 2026. He is currently the chairman and CEO of CorMedix Inc., bringing over two decades of executive experience in the pharmaceutical and biotechnology industries. His track record includes substantial achievements in business strategy, corporate development, and entrepreneurship.

Marc Salzberg, MD, chairman and CEO of Airway Therapeutics, highlighted the invaluable contributions Todisco is poised to bring to the company. “Joe's robust experience in establishing and developing specialized pharmaceutical firms, coupled with his strategic perspective across commercial and operational functions, will be instrumental in advancing our lead candidate, zelpultide alfa, into the next phase of development and preparing for its potential market launch,” said Salzberg.

Zelpultide alfa, currently in advanced clinical development, aims to prevent bronchopulmonary dysplasia (BPD) in very preterm infants—a significant medical need lacking an approved preventive treatment. With Todisco's extensive network and insights into product commercialization within hospital settings, Airway Therapeutics is well-positioned to approach the marketplace effectively.

In his own words, Todisco expressed excitement about this pivotal moment for the company. “I look forward to collaborating with the board to advance Airway’s project portfolio and strategic vision. Airway’s innovative approach to biologic therapies, particularly with zelpultide alfa, has the potential to meet crucial unmet medical needs, including BPD,” he noted.

Prior to his role at CorMedix, Todisco held various high-ranking positions at Amneal Pharmaceuticals over an eleven-year tenure, including Chief Commercial Officer of Amneal Specialty and Senior Vice President of Business Development and International Operations. His experience also spans significant leadership roles at Ranbaxy Pharmaceuticals and Par Pharmaceuticals, focusing on commercial strategies and business growth.

A Georgetown University graduate with a degree in economics, Todisco also holds an MBA from Fordham’s Graduate School of Business. His extensive background equips him with the necessary skills to contribute to Airway Therapeutics during a critical phase of growth.

Airway Therapeutics is committed to reimagining the prevention and treatment of respiratory diseases through advanced biologic therapies. Along with zelpultide alfa, the company is exploring broader applications for their biologic platform to enhance patient outcomes across diverse age groups and medical conditions.

For further information regarding Airway Therapeutics and its innovative approaches, visit their website at Airway Therapeutics.